Progress in the biomarker discovery for drug-induced liver injury / 药学学报
Acta Pharmaceutica Sinica
;
(12): 959-965, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-257041
ABSTRACT
The leading cause of drug withdrawal from market and clinical trials failure is drug-induced liver injury (DILI). Varying clinical, histological and laboratory features of DILI, as well as undefined underlying mechanisms, hinder patients to be diagnosed in the early-stage of the disease and receive effective treatments. Conventional indicators, like serum transaminases and bilirubin, have inevitable limitations referring to sensitive prediction and specific detection of DILI. In order to reduce the occurrence of DILI, researchers have attempted to discover potential biomarkers with higher specificity and sensitivity from blood and urine in recent years. This article aims to review recent advances in biomarkers of DILI.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Urine
/
Blood
/
Biomarkers
/
Sensitivity and Specificity
/
Diagnosis
/
Chemical and Drug Induced Liver Injury
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS